Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Glioblastoma 4Glioma 3Neoplasms 2Multiple Myeloma 2Lymphoma 2Astrocytoma 2Whooping Cough 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumococcal Infections 1Papillomavirus Infections 1Pancreatic Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Medulloblastoma 1Measles 1Lymphoma, Non-Hodgkin 1Lipodystrophy, Congenital Generalized 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Human Papillomavirus-Related Cervical Carcinoma 1Hodgkin Disease 1Hepatitis B 1

Interventions

adacel 1Tetanus Toxoid 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Diphtheria-Tetanus-acellular Pertussis Vaccines 1Diphtheria-Tetanus Vaccine 1Diphtheria Toxoid 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Fallopian Tube Carcinoma × Tetanus Toxoid × Clear all
NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Mayo Clinic

Phase 2 Recruiting
78 enrolled
GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡